Home >Research Technology Management>Technology for Licensing

Assays & Technologies

Assay Dev & Screening Group and Technology Development Platforms

Anti-HIV cell-based assay(s) [Code No: IPK0901]

This cell-based, high-content screening assay using 384-well plates is used to evaluate all steps of the HIV life cycle.

5-HT2C receptor internalization assay [Code No: IPK0902]

This cell-based, high-content screening assay using 384-well plates is used to evaluate 5-HT2C GPCR receptor internalization.

Leptin receptor internalization assay [Code No: IPK0903]

This cell-based, high-content screening assay using 384-well plates is used to evaluate leptin receptor (OBR) internalization.

Tau protein phosphorylation assay [Code No: IPK0904]

This cell-based, high-content screening assay using 384-well plates is used to evaluate tau protein expression and phosphorylation.

Gamma secretase activity assay [Code No: IPK0905]

This cell-based, high-content screening assay using 384-well plates is used to evaluate gamma-secretase activity.

Beta secretase activity assay [Code No: IPK0906]

This cell-based, high-content screening assay using 384-well plates is used to evaluate beta-secretase 1 or 2 activity.

Cell-based assay development and optimization for HCS [Code No: IPK0907]

This includes developing and optimizing cell-based, high-throughput screening and high-content assays; acquiring and analyzing screening data; and compiling and reporting the final results. Assay development is performed in 384-well plates.

Cell-based assay development and optimization for PPI [Code No: IPK0908]

This entails developing and optimizing live cell-based assays for protein-protein interaction (PPI) quantification, acquiring and analyzing screening data, and compiling and reporting the final results. Assay development is performed in 96- or 384-well plates.

Cell-based assay high-throughput screening for chronic/infectious disease using adapted biosafety facility [Code No: IPK0909]

We perform automated high-throughput screening and high-content screening using a multimode plate reader or automated confocal microscope in biosafety facilities up to level three. Screening libraries are arrayed in 384-well microtiter plates.